Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Overview of attention for article published in Annals of Oncology, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 3 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 3 X users

patent: 1 patent
wikipedia: 1 Wikipedia page
reddit: 1 Redditor

Readers on

mendeley: 202 Mendeley

So far, Altmetric has seen 5 news stories from 3 outlets.

La aprobación de Elahere amplía las opciones de tratamiento para algunos cánceres de ovario avanzados

National Cancer Institute, 30 May 2024

30 de mayo de 2024, por Linda Wang Los conjugados anticuerpo-fármaco constan de un anticuerpo (amarillo) que se une a un…

Treatment Options Expand for Some Advanced Ovarian Cancers

National Cancer Institute, 24 Apr 2024

April 24, 2024, by Linda Wang Antibody–drug conjugates include an antibody (yellow) attached to a cytotoxic drug (red spiky ball…

Antibody-Drug Conjugates Pose Risk of Ocular Adverse Effects

Cancer Therapy Advisor, 30 Aug 2023

The ocular toxicities observed in patients treated with antibody-drug conjugates (ADCs) have prompted the development of…

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

OncLive, 16 Jan 2023

Ursula A. Matulonis, MD Folate metabolism has been successfully targeted in anticancer therapy for nearly 75 years, starting…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.